Advertisement

Topics

Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

07:58 EDT 28 Jul 2017 | The Street

Click to view a price quote on LLY.

Click to research the Drugs industry.

Original Article: Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

NEXT ARTICLE

More From BioPortfolio on "Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly"

Quick Search
Advertisement